PRODUCTION OF HUMAN ANTIMALARIAL CRISIS FORM FACTOR

人类抗疟危机因子的生产

• 批准号: 3488419
• 负责人: JEFFREY F WILLIAMS
• 金额: $ 5万
• 依托单位: PROBE-TEK, INC.
• 依托单位国家: 美国
• 财政年份: 1986
• 资助国家: 美国
• 起止时间: 1986-05-01 至 1986-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3488419
• 关键词: Plasmodium; Plasmodium falciparum; antimalarial agents; antimicroorganism antibody; antiserum; cellular immunity; high performance liquid chromatography; human tissue; hybridomas; immunologic techniques; immunotherapy; ion exchange chromatography; lymphokines; malaria; malaria vaccines; microorganism immunology; molecular sieving; monoclonal antibody; parasitic disease chemotherapy; protozoal antigen; reversed phase chromatography

Malaria, due to Plasmodium falciparum remains the most important human infectious disease in the world. Past control measures have been inadequate to limit the incidence and consequences of the disease. Currently, a great deal of attention and funding is being directed to the search for an antimalarial vaccine. These programs support the search for parasite antigens which could stimulate protective immunity in humans via antibody-dependent mechanisms. However, the acquired protective immunity to malaria found in humans living in malarious areas is poorly understood. It is possible, if not likely, that vaccines based on antibody alone will be of relatively limited use in controlling malaria. Jensen et al reported strong evidence that naturally acquired immunity to falciparum malaria in Sudan involves a major contribution from cell-mediated immune responses. In vitro, Sudanese immune sera cause a profound retardation in the intraerythrocytic development of P. falciparum resulting in the appearance of morphologically typical "crisis forms." We have termed the factor responsible for the activity crisis-form factor (CFF). The long term objectives of this research are to be able to produce CFF for use as a possible therapeutic agent in the clinical management of malaria, or to stimulate production of protective substance in vivo as a potential means of prophylaxis. Both approaches require the purification, characterization and specific quantitation of CFF from human immune serum sources. The specific aim of the Phase 1 feasibility study is to develop immunoassay procedures based on the production of anti-CFF monoclonal antibodies.

疟疾，由于恶性疟原虫，疟疾仍然是最重要的人类 世界上传染病。 过去的控制措施已经 不足以限制疾病的发生率和后果。 目前，正在关注和资金。 寻找抗疟疾疫苗。 这些程序支持搜索 可以通过 抗体依赖机制。 但是，获得的保护性免疫 在生活在疟疾地区的人类中发现的疟疾知之甚少。 如果不可能，仅基于抗体的疫苗就有可能 控制疟疾的用途相对有限。 詹森等人报道了 有力的证据表明，自然获得对恶性疟疾的免疫力 苏丹涉及细胞介导的免疫反应的主要贡献。 在体外，苏丹免疫血清在 恶性疟原虫的肠内发育导致外观 形态上典型的“危机形式”。 我们称之为因素 负责活动危机形式因素（CFF）。 长期 这项研究的目标是能够生产CFF作为一个 疟疾临床管理中可能的治疗剂，或 刺激体内保护物质的产生，作为潜在手段 预防。 两种方法都需要纯化，表征 以及来自人类免疫血清来源的CFF的特定定量。 这 第1阶段可行性研究的具体目的是开发免疫测定 基于抗CFF单克隆抗体的产生的程序。